Sian Cooper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sian Cooper has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
Alex Dunlop
The Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
4 shared publicationsAlison C. Tree
The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
4 shared publicationsSophie Alexander
The Royal Marsden NHS Foundation Trust, London, UK
4 shared publicationsAlison Tree
The Royal Marsden Hospital NHS FT, Sutton SM2 5PT, UK; The Institute of Cancer Research, Sutton, UK
3 shared publicationsEmma Hall
3 shared publicationsStephanie Burnett
3 shared publications
Latest Publications
- 20 October 2026
- Published by Elsevier in European Urology
In Response to “Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?” Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.07.023
- 20 October 2026
- Published by Elsevier in European Urology
In Response to “Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?” Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.07.023
- Open Access
- 20 July 2026
- Published by Elsevier in European Urology
- Vol. 90 (4) , 321-327
Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial
- 20 July 2026
- Published by Elsevier in European Urology
- Vol. 90 (4) , 321-327
Open AccessPatient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial
- Open Access
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial
Introduction: Stereotactic body radiotherapy (SBRT) delivered on an MRI-guided linear accelerator (MR-linac) enables highly conformal prostate cancer irradiation. The DESTINATION 2 trial is a federated, randomised phase II/R-IDEAL 2b study evaluating whether de-escalating the dose to prostate tissue, while maintaining a high dose to MRI-visible tumour(s) in two fractions, reduces genitourinary (GU) treatment-related adverse events (AE) without compromising disease control in men with localised prostate cancer. Methods: 200 men worldwide with localised, MRI-visible prostate cancer will be randomised 1:1 to receive either (1) prescribed uniform dose MR-linac SBRT (27 Gy in two fractions to the whole prostate and seminal vesicles with 0 mm CTV-PTV margin) or (2) de-escalated SBRT (20 Gy in two fractions to whole prostate with 0 mm CTV-PTV margin and 27 Gy in two fractions to MRI-visible tumour(s) with a 4 mm intraprostatic margin applied to the GTV. All treatments are delivered using MRI-guided adaptive Radiotherapy (MRIgRT). The primary endpoint is the absolute and relative risk reduction in acute grade 2+GU AE (CTCAE v5) within 12 weeks of completing radiotherapy. Secondary endpoints include late GU AE, acute and late gastrointestinal (GI) AE, sexual AE, patient-reported outcomes, dosimetry, technical feasibility and 2-year biochemical relapse-free survival. Ethics and dissemination: This is a federated trial design in which each centre operates independently with its own sponsor, ethics committee approval and regulatory oversight. Each centre is responsible for obtaining and maintaining local ethics approval in accordance with their national and institutional requirements. The UK centre (The Royal Marsden NHS Foundation Trust) has received ethical approval from the East of England–Cambridge South Research Ethics Committee (REC reference: 24/EE/0163; IRAS: 338368). Results will be disseminated via peer-reviewed publications and conference presentations. Trial registration number: NCT06638541 .
Open AccessDose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial
Introduction: Stereotactic body radiotherapy (SBRT) delivered on an MRI-guided linear accelerator (MR-linac) enables highly conformal prostate cancer irradiation. The DESTINATION 2 trial is a federated, randomised phase II/R-IDEAL 2b study evaluating whether de-escalating the dose to prostate tissue, while maintaining a high dose to MRI-visible tumour(s) in two fractions, reduces genitourinary (GU) treatment-related adverse events (AE) without compromising disease control in men with localised prostate cancer. Methods: 200 men worldwide with localised, MRI-visible prostate cancer will be randomised 1:1 to receive either (1) prescribed uniform dose MR-linac SBRT (27 Gy in two fractions to the whole prostate and seminal vesicles with 0 mm CTV-PTV margin) or (2) de-escalated SBRT (20 Gy in two fractions to whole prostate with 0 mm CTV-PTV margin and 27 Gy in two fractions to MRI-visible tumour(s) with a 4 mm intraprostatic margin applied to the GTV. All treatments are delivered using MRI-guided adaptive Radiotherapy (MRIgRT). The primary endpoint is the absolute and relative risk reduction in acute grade 2+GU AE (CTCAE v5) within 12 weeks of completing radiotherapy. Secondary endpoints include late GU AE, acute and late gastrointestinal (GI) AE, sexual AE, patient-reported outcomes, dosimetry, technical feasibility and 2-year biochemical relapse-free survival. Ethics and dissemination: This is a federated trial design in which each centre operates independently with its own sponsor, ethics committee approval and regulatory oversight. Each centre is responsible for obtaining and maintaining local ethics approval in accordance with their national and institutional requirements. The UK centre (The Royal Marsden NHS Foundation Trust) has received ethical approval from the East of England–Cambridge South Research Ethics Committee (REC reference: 24/EE/0163; IRAS: 338368). Results will be disseminated via peer-reviewed publications and conference presentations. Trial registration number: NCT06638541 .
- Open Access
- 6 January 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 216, 111363
Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study
- 6 January 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 216, 111363
Open AccessAcute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study
- Open Access
- 19 November 2025
- Published by Elsevier in Physica Medica
- Vol. 140, 105188
Evaluation of domain shift sources and generalisability in AI-based prostate MRI autocontouring for radiotherapy
- 19 November 2025
- Published by Elsevier in Physica Medica
- Vol. 140, 105188
Open AccessEvaluation of domain shift sources and generalisability in AI-based prostate MRI autocontouring for radiotherapy
- Open Access
- 23 July 2025
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 98 (1174) , 1591-1595
Towards simulation free radiotherapy
Objectives: The standard radiotherapy (RT) pathway faces bottlenecks. The RACE study aims to evaluate the feasibility and safety of "simulation-free" radiotherapy (SFRT) by using diagnostic, non-radiotherapy-dedicated magnetic resonance (MR) scans for planning prostate cancer treatments with MRI-guided online adaptive radiotherapy (MRIgART). Methods: In the first step of RACE, we conducted an audit of prostate cancer patients who received 5-fraction stereotactic body radiotherapy(SBRT) between March 2023 and January 2024, evaluating their diagnostic MRI scans for potential use in RT planning. The key requirements for planning suitability were a T2-weighted sequence for target/OAR delineation and a large field-of-view scan for body contour and bones, with scans categorized as either fully suitable or having specific issues (incomplete body coverage or slice thickness >10mm). Workflow analysis measured time intervals between RT referral, planning MRI, and first fraction to quantify potential time savings from SRFT. Results: Diagnostic MRIs were available for 93% of patients, with scans originating from various hospitals and conducted on 1.5 Tesla (T) or 3T MRI scanners. Ideal image characteristics for RT planning were met in 31% of MRIs. Issues such as cropped field of view (FOV) and low slice resolution were identified, but proposed solutions could increase the number of patients with suitable scans to 87%. Conclusions: The findings suggest that with appropriate technical solutions, most diagnostic MRI scans can be adapted for RT planning purposes.
- 23 July 2025
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 98 (1174) , 1591-1595
Open AccessTowards simulation free radiotherapy
Objectives: The standard radiotherapy (RT) pathway faces bottlenecks. The RACE study aims to evaluate the feasibility and safety of "simulation-free" radiotherapy (SFRT) by using diagnostic, non-radiotherapy-dedicated magnetic resonance (MR) scans for planning prostate cancer treatments with MRI-guided online adaptive radiotherapy (MRIgART). Methods: In the first step of RACE, we conducted an audit of prostate cancer patients who received 5-fraction stereotactic body radiotherapy(SBRT) between March 2023 and January 2024, evaluating their diagnostic MRI scans for potential use in RT planning. The key requirements for planning suitability were a T2-weighted sequence for target/OAR delineation and a large field-of-view scan for body contour and bones, with scans categorized as either fully suitable or having specific issues (incomplete body coverage or slice thickness >10mm). Workflow analysis measured time intervals between RT referral, planning MRI, and first fraction to quantify potential time savings from SRFT. Results: Diagnostic MRIs were available for 93% of patients, with scans originating from various hospitals and conducted on 1.5 Tesla (T) or 3T MRI scanners. Ideal image characteristics for RT planning were met in 31% of MRIs. Issues such as cropped field of view (FOV) and low slice resolution were identified, but proposed solutions could increase the number of patients with suitable scans to 87%. Conclusions: The findings suggest that with appropriate technical solutions, most diagnostic MRI scans can be adapted for RT planning purposes.
- Open Access
- 19 July 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 211, 111053
Towards rapid and efficient simulation-free radiotherapy: MR guided adaptive prostate radiotherapy on the MR-Linac using diagnostic MRI reference planning
- 19 July 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 211, 111053
Open AccessTowards rapid and efficient simulation-free radiotherapy: MR guided adaptive prostate radiotherapy on the MR-Linac using diagnostic MRI reference planning
- Open Access
- 20 May 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (3) , 773-782
HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging–Guided Adaptive Prostate Radiation Therapy
- 20 May 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (3) , 773-782
Open AccessHERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging–Guided Adaptive Prostate Radiation Therapy
- Open Access
- 2 April 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (1) , 171-182
Standardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT)
- 2 April 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (1) , 171-182
Open AccessStandardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT)
- Open Access
Upper Urinary Tract Stereotactic Body Radiotherapy Using a 1.5 Tesla Magnetic Resonance Imaging-Guided Linear Accelerator: Workflow and Physics Considerations
Background/Objectives: Advancements in radiotherapy technology now enable the delivery of ablative doses to targets in the upper urinary tract, including primary renal cell carcinoma (RCC) or upper tract urothelial carcinomas (UTUC), and secondary involvement by other histologies. Magnetic resonance imaging-guided linear accelerators (MR-Linacs) have shown promise to further improve the precision and adaptability of stereotactic body radiotherapy (SBRT). Methods: This single-institution retrospective study analyzed 34 patients (31 with upper urinary tract non-metastatic primaries [RCC or UTUC] and 3 with metastases of non-genitourinary histology) who received SBRT from August 2020 through September 2024 using a 1.5 Tesla MR-Linac system. Treatment plans were adjusted by using [online settings] for “adapt-to-position” (ATP) and “adapt-to-shape” (ATS) strategies for anatomic changes that developed during treatment; compression belts were used for motion management. Results: The median duration of treatment was 56 min overall and was significantly shorter using the adapt-to-position (ATP) (median 54 min, range 38–97 min) in comparison with adapt-to-shape (ATS) option (median 80, range 53–235 min). Most patients (77%) experienced self-resolving grade 1–2 acute radiation-induced toxicity; none had grade ≥ 3. Three participants (9%) experienced late grade 1–2 toxicity, potentially attributable to SBRT, with one (3%) experiencing grade 3. Conclusions: We conclude that MR-Linac-based SBRT, supported by online plan adaptation, is a feasible, safe, and highly precise treatment modality for the definitive management of select upper urinary tract lesions.
Open AccessUpper Urinary Tract Stereotactic Body Radiotherapy Using a 1.5 Tesla Magnetic Resonance Imaging-Guided Linear Accelerator: Workflow and Physics Considerations
Background/Objectives: Advancements in radiotherapy technology now enable the delivery of ablative doses to targets in the upper urinary tract, including primary renal cell carcinoma (RCC) or upper tract urothelial carcinomas (UTUC), and secondary involvement by other histologies. Magnetic resonance imaging-guided linear accelerators (MR-Linacs) have shown promise to further improve the precision and adaptability of stereotactic body radiotherapy (SBRT). Methods: This single-institution retrospective study analyzed 34 patients (31 with upper urinary tract non-metastatic primaries [RCC or UTUC] and 3 with metastases of non-genitourinary histology) who received SBRT from August 2020 through September 2024 using a 1.5 Tesla MR-Linac system. Treatment plans were adjusted by using [online settings] for “adapt-to-position” (ATP) and “adapt-to-shape” (ATS) strategies for anatomic changes that developed during treatment; compression belts were used for motion management. Results: The median duration of treatment was 56 min overall and was significantly shorter using the adapt-to-position (ATP) (median 54 min, range 38–97 min) in comparison with adapt-to-shape (ATS) option (median 80, range 53–235 min). Most patients (77%) experienced self-resolving grade 1–2 acute radiation-induced toxicity; none had grade ≥ 3. Three participants (9%) experienced late grade 1–2 toxicity, potentially attributable to SBRT, with one (3%) experiencing grade 3. Conclusions: We conclude that MR-Linac-based SBRT, supported by online plan adaptation, is a feasible, safe, and highly precise treatment modality for the definitive management of select upper urinary tract lesions.